Covid 19 Research using Clinical Trials (Home Page)
Report for D003680: Deglutition Disorders NIH
(Synonyms: Deglutition Disorders)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (1)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug807 | Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) Wiki | 1.00 |
Correlated MeSH Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There is one clinical trial.
Clinical Trials
1 Oropharyngeal Dysphagia in Patients Infected by SARS-CoV-2: Prevalence and Needs of Compensatory Treatment of Patients Admitted by COVID-19 in the Consorci Sanitari Del Maresme
Background: Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute hospitals to rehabilitation centers, nursing homes or other facilities. All these situations are common for COVID-19 patients that are currently filling our hospitals due to the pandemic expansion of SARS-CoV-2. OD is associated to prolonged hospitalization, dehydration and severe nutritional and respiratory complications -aspiration pneumonia-, hospital readmissions and mortality. Aim: to assess the prevalence of OD in these patients and to know their needs of compensatory treatment. Methods: observational study in which we will use the volume-viscosity swallowing test (V-VST) to assess the prevalence of OD in admitted patients with confirmed COVID-19 at the Consorci Sanitari del Maresme. We will register also results of the EAT-10, nutritional status (MNA-sf/MUST/NRS), the needs of compensatory treatments of these patients (fluid and nutritional adaptation and use of nutritional supplements) and clinical complications during 6 months follow up.
NCT04346212 Oropharyngeal Dysphagia COVID-19 Sars-CoV2 Nutrition Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) MeSH:Deglutition Disorders
HPO:Dysphagia Oral-pharyngeal dysphagia
Primary Outcomes
Description: Prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).
Measure: Prevalence of oropharyngeal dysphagia Time: From April to July 2020.
Secondary Outcomes
Description: Eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points
Measure: Swallowing screening Time: From April to July 2020.
Description: Percentage of patients with impairements in efficacy and/or safety of swallow.
Measure: Swallowing status. Time: From April to July 2020.
Description: Nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).
Measure: Nutritonal status of study patient's. Time: From April to July 2020.
Description: Fluid (volume and viscosity) requirements of study patients.
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation). Time: From April to July 2020.
Description: Nutritional adaptation requirements (type of diet and need of nutritional supplementation).
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation). Time: From April to July 2020.
Description: Incidence of hospital readmissions: number of hospital readmissions/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions). Time: 6 months from inclusion.
Description: Prevalence: % of patients with hospital readmissions during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions). Time: 6 months from inclusion.
Description: Incidence: number of visits to the emergency department/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department). Time: 6 months from inclusion.
Description: Prevalence: % of patients visiting the emergency department during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department). Time: 6 months from inclusion.
Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).
Measure: Clinical complications at 6 months follow up from patient's medical history (respiratory complications). Time: 6 months from inclusion.
Description: 6 months mortality.
Measure: Clinical complications at 6 months follow up from patient's medical history (mortality). Time: 6 months from inclusion.
HPO Nodes
HP:0002015: Dysphagia
Genes 470
TIMM8A SIK1 CACNA1A ND5 PLAA GMPPA RNASEH1 ALS2 CYP27A1 ATXN3 DNAJC13 OPA1 QDPR MYPN CHRNE KLHL40 ADH1C TYMP MSX1 NEK1 MPZ TAF1 FUS LMNB1 PLEC KIT SCN3A ATXN8OS SLC52A3 SOD1 SNCA COLQ IRF2BPL PIGA MYO9A SCN4A SLC18A3 LAMA2 GBA NGLY1 POLG TBCD COL7A1 SPG7 ND2 DKK1 CRYAB CACNA1G C9ORF72 RRM2B NPC2 SURF1 SDHB GBA SPG7 SELENON CYP7B1 LINGO1 TOP3A NRXN1 KAT6B PUF60 UBTF NDUFA9 UBB NECTIN1 COL7A1 BRAF LMOD3 NDUFS2 COQ2 MYH7 ASAH1 PLEC ATXN3 SNCAIP NEB REPS1 RAI1 ADAR RLIM RARS1 MYO9A SYT14 NDUFS1 FXN SLC25A22 ITGB4 SDHC VAMP1 PSEN1 ASCC1 ARHGAP29 DLX4 DDHD2 ALDH18A1 MMP1 LAMB2 MYH8 SLC5A7 NONO PYROXD1 SKI SACS ASPA POLG TRAPPC12 TWNK SPECC1L TPM2 IDH1 GNS MATR3 SERPING1 MAPT CHMP2B PRDM16 GNAQ APP GEMIN4 ERLIN2 SLC52A3 C19ORF12 ND4 NGLY1 CHRND STUB1 POLG CCR6 UBQLN2 MED17 GABRD B4GALNT1 NR4A2 CARMIL2 CAV1 SDHB CHD7 SEMA3E IRF5 NEUROD2 TK2 CACNA1G POLG MECR FARS2 SETX VAPB PANK2 GBA NDUFB8 CHAT TK2 ATP7B CARS2 KCNC3 NDUFA6 VAMP1 KLHL7 PNKD ACTA1 CCN2 VAMP1 ADNP HPCA TBP SYNJ1 TTBK2 MATR3 ATXN1 DLG1 KIT MAPT PSAP TPM3 SLC25A1 SLC5A7 BMP4 PFN1 NOTCH3 REEP1 ATXN8 KIT MYOT SCN4A PLP1 NDUFS3 KIAA0319L FTL SLC52A2 CHCHD10 SLC6A9 DYSF POLR3A SDHD ATP1A3 CNTNAP1 TIMM8A POLR3A NOP56 FBXO7 PDGFRA KCNK9 SCN4A SYT2 PANK2 RRM2B RRM2B PLAA PRPS1 ERLIN2 SLC9A6 SDHA EIF4G1 POLG DNAJB6 CHRNE TPM2 LMNB1 EBF3 VPS35 MAP2K2 SPG21 TUBB4A COL7A1 ATP6 CDC73 NECTIN1 TP63 SLC52A2 XRCC1 NEFH ATXN2 COL7A1 MID1 NUP62 FRG1 HOXB1 SDHC ZFYVE26 PRPH SON REEP1 TRNW ND6 TBP SYT14 SQSTM1 PMP22 TRNV OPTN PLA2G6 SPG7 PRKCG RERE NDUFAF3 DNAJB6 PLA2G6 KCND3 GDAP2 GBA HLA-B SLC52A3 IRX5 TARDBP ATN1 IDH2 AGRN TWNK PTS ACTG2 POLR3B PRKRA PEX16 ATXN7 PANK2 SCARB2 GLUD2 PTS GCH1 LRRK2 SQSTM1 MACF1 DMPK PDE8B MAPT ACTB MAPT HPRT1 PCNA CHRND IRF5 CTNS TARDBP ANKRD11 HLA-DRB1 ALS2 PANK2 COQ4 FBXL4 NPC1 FLCN CDH1 ATXN3 SNCA GRHL2 SMC1A SCN4A VARS1 ACTA1 SLC25A4 LBR MYORG GRIN2D DNM1L HLA-DRB1 ATP6 MSX1 WFS1 CCR6 KLHL41 PIK3R5 SLC19A3 ACTA1 HTT MAPT ATXN10 POLG GRHL3 ATXN8 TAF1 TPM3 ACTA1 SETX HGSNAT SETBP1 ECM1 NCAPG2 COL7A1 MFF RNASEH1 IRF6 ATP13A2 ATP1A3 COLQ POLR3A KBTBD13 ACTA1 CLCN1 EPRS1 CAVIN1 KIF5A FMR1 DGUOK ATP7A ATP1A3 TUBB4A LIFR TK2 RYR1 KY GBA2 SNAP25 ND3 POLG2 SDHC ATXN8OS TGM6 GUCY1A1 PLXND1 LRP12 SPART VCP SLC9A6 AFG3L2 ARX PDP1 NEB TAF1 PRNP SDHB NF1 MAPT EXOSC9 ALS2 DGUOK ATXN3 DCTN1 GRM1 MYOT NDUFAF2 AFG3L2 STUB1 GNAO1 MEGF10 TPM3 SPG11 CHAT RHBDF2 CAV1 VAC14 DAB1 CHCHD10 ATXN1 POLR3B CACNA1A NUP62 ATXN7 FTL TRIP4 KLHL41 TRNL1 MECP2 KLHL40 SPG21 ND1 PABPN1 KMT2A ACOX1 TBK1 PIGN IKZF1 CCN2 VPS13A CDC73 ATXN8OS NEB IRF6 SCO2 ATXN2 PRKRA TP63 MGME1 GIGYF2 ALS2 TANGO2 ADD3 AR TRNK FLAD1 COL13A1 KCNK9 CHMP1A VAMP1 ERLIN2 TPM3 REV3L NOP56 FA2H QDPR CNTNAP2 KLHL41 YARS2 CHRNA1 GFPT1 FERMT1 DDHD2 KCNAB2 NEB TBC1D23 MYMK GBA MMP1 ADCY6 TBK1 GJB1 CHRNA1 RRM2B TUBB6 SNCA Protein Mutations 1
V158M SNP 0
Primary Outcomes
Description: Prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).
Measure: Prevalence of oropharyngeal dysphagia Time: From April to July 2020.Secondary Outcomes
Description: Eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points
Measure: Swallowing screening Time: From April to July 2020.Description: Percentage of patients with impairements in efficacy and/or safety of swallow.
Measure: Swallowing status. Time: From April to July 2020.Description: Nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).
Measure: Nutritonal status of study patient's. Time: From April to July 2020.Description: Fluid (volume and viscosity) requirements of study patients.
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation). Time: From April to July 2020.Description: Nutritional adaptation requirements (type of diet and need of nutritional supplementation).
Measure: Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation). Time: From April to July 2020.Description: Incidence of hospital readmissions: number of hospital readmissions/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions). Time: 6 months from inclusion.Description: Prevalence: % of patients with hospital readmissions during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions). Time: 6 months from inclusion.Description: Incidence: number of visits to the emergency department/patient/6 months.
Measure: Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department). Time: 6 months from inclusion.Description: Prevalence: % of patients visiting the emergency department during the follow-up.
Measure: Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department). Time: 6 months from inclusion.Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).
Measure: Clinical complications at 6 months follow up from patient's medical history (respiratory complications). Time: 6 months from inclusion.Description: 6 months mortality.
Measure: Clinical complications at 6 months follow up from patient's medical history (mortality). Time: 6 months from inclusion.